| Eye Physicians, P.c. | |
|
3772 43rd Ave, Suite A, Columbus, NE 68601-1681 | |
| (402) 563-3688 | |
| (402) 564-1797 |
| Full Name | Eye Physicians, P.c. |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 3772 43rd Ave, Columbus, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497732895 | NPI | - | NPPES |
| 02836 | Other | NE | BLUE CROSS BLUE SHIELD OF |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (Nebraska) | Primary |
| Provider Name | Kerry Jo Krings |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1730137027 PECOS PAC ID: 0143267716 Enrollment ID: I20050415000511 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Jennifer Ann Furstenau |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1144334624 PECOS PAC ID: 3476557257 Enrollment ID: I20060909000035 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Peter E Diedrichsen |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1194702597 PECOS PAC ID: 9638276108 Enrollment ID: I20070517000153 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Sarah E Langan |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1386809655 PECOS PAC ID: 4880761873 Enrollment ID: I20080917000029 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Ryan Glenn Palmer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1437374659 PECOS PAC ID: 8224125265 Enrollment ID: I20100615000901 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Russell M Vetick |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1487631818 PECOS PAC ID: 7416046784 Enrollment ID: I20100920000134 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Jeffrey S Saum |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1154308583 PECOS PAC ID: 4789773052 Enrollment ID: I20100920000154 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | William C Meyer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1073590352 PECOS PAC ID: 1153410428 Enrollment ID: I20100920000179 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Richard W Meyer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1982681318 PECOS PAC ID: 0244329514 Enrollment ID: I20100920000198 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Richard P Haney |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1386621704 PECOS PAC ID: 8426147794 Enrollment ID: I20100920000209 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Andrew J Baldwin |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1336551571 PECOS PAC ID: 5698990315 Enrollment ID: I20180530002935 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Provider Name | Patrick S Kelley |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1508853128 PECOS PAC ID: 6709850894 Enrollment ID: I20230209000399 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eye Physicians, P.c. Po Box 1275, Columbus, NE 68602-1275 Ph: (402) 563-3688 | Eye Physicians, P.c. 3772 43rd Ave, Suite A, Columbus, NE 68601-1681 Ph: (402) 563-3688 |
News Archive
When scientists study cells, they need to know how much oxygen each cell consumes to determine its metabolism. However, existing technology limits this study to groups of cells, not individual cells. Lihong Wang, PhD, plans to change that.
AVANIR Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent for its lead drug candidate Zenvia™ (dextromethorphan/quinidine), extending the period of patent protection in the United States into late 2025. U.S. patent number 7,659,282 titled "Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders" was issued on February 9, 2010. The new patent will provide AVANIR with patent protection for low-dose quinidine formulations of Zenvia used to treat pseudobulbar affect (PBA).
About half of the car trips in the U.S. are less than five miles - a distance easily navigated by walking or cycling. Reducing short-distance car trips has many benefits - it decreases car accidents, has positive benefits for the environment and increases physical health and activity, says communication professor Edward Maibach of George Mason University. An expert in climate change communication research, Maibach says that community leaders should make promotion of physical activity a priority.
Following the death of a 5-year-old patient, a dentist in Chicago has had his license to practice suspended by State regulators.
› Verified 1 days ago
Unity Eye Centers Inc Optometrist Medicare: Medicare Enrolled Practice Location: 605 23rd St, Columbus, NE 68601 Phone: 402-564-0545 Fax: 402-564-0078 | |
Dr. Larry E Malicky, OD FAAO Optometrist Medicare: Not Enrolled in Medicare Practice Location: 566 S Quail Ln, Columbus, NE 68601 Phone: 402-561-0545 Fax: 402-564-0078 | |
Dr. Dennis W Kappenman Jr., O.D. Optometrist Medicare: Medicare Enrolled Practice Location: Walmart Vision Center, 818 E. 23rd Street, Columbus, NE 68601 Phone: 402-564-0474 | |
Dr. Cody Michael Lay, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 818 E 23rd St, Columbus, NE 68601 Phone: 402-564-0474 Fax: 402-562-5488 | |
Larry E Malicky Od Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 566 S Quail Ln, Columbus, NE 68601 Phone: 402-980-4787 | |
Richard P Haney, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 3772 43rd Ave, Suite A, Columbus, NE 68601 Phone: 402-563-3686 Fax: 402-564-1797 | |
Dr. Daniel Keith Mickey, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1371 29th Ave, Columbus, NE 68601 Phone: 402-564-0545 Fax: 402-564-0078 |